Published • loading... • Updated
Anti-Müllerian Hormone Predicts Benefit of Chemo + Endocrine Therapy in Under-55s with Breast Cancer
Summary by Medical Xpress
3 Articles
3 Articles
Anti-Müllerian hormone predicts benefit of chemo + endocrine therapy in under-55s with breast cancer
Anti-Müllerian hormone (AMH) appears to predict the benefit of chemotherapy plus endocrine therapy (CET) versus ET alone in premenopausal women younger than 55 years with hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer with a recurrence score (RS) ≤25, according to a study published online July 24 in the Annals of Oncology.
·Douglas, United Kingdom
Read Full Article
More than ten thousand packages of tamoxifen medicine for breast cancer patients will arrive in the Czech Republic from abroad. Some packages are already in pharmacies, while others will only be delivered by distributors. The Ministry of Health promises further deliveries of the long-missing drug in the autumn.
Coverage Details
Total News Sources3
Leaning Left0Leaning Right0Center1Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium
